|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC26A6 |
Gene summary for SLC26A6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC26A6 | Gene ID | 65010 |
| Gene name | solute carrier family 26 member 6 | |
| Gene Alias | SLC26A6 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A0C4DFT5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65010 | SLC26A6 | HCC1_Meng | Human | Liver | HCC | 3.68e-16 | 3.86e-02 | 0.0246 |
| 65010 | SLC26A6 | HCC1 | Human | Liver | HCC | 8.47e-07 | 2.84e+00 | 0.5336 |
| 65010 | SLC26A6 | HCC2 | Human | Liver | HCC | 8.29e-17 | 3.71e+00 | 0.5341 |
| 65010 | SLC26A6 | S014 | Human | Liver | HCC | 1.38e-03 | 2.39e-01 | 0.2254 |
| 65010 | SLC26A6 | S015 | Human | Liver | HCC | 1.92e-09 | 5.18e-01 | 0.2375 |
| 65010 | SLC26A6 | S016 | Human | Liver | HCC | 1.39e-03 | 2.68e-01 | 0.2243 |
| 65010 | SLC26A6 | S027 | Human | Liver | HCC | 6.26e-06 | 5.99e-01 | 0.2446 |
| 65010 | SLC26A6 | S028 | Human | Liver | HCC | 4.20e-19 | 7.97e-01 | 0.2503 |
| 65010 | SLC26A6 | S029 | Human | Liver | HCC | 7.21e-27 | 1.13e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000974322 | Liver | HCC | response to carbohydrate | 149/7958 | 253/18723 | 9.55e-08 | 1.89e-06 | 149 |
| GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
| GO:000974622 | Liver | HCC | response to hexose | 126/7958 | 219/18723 | 4.81e-06 | 6.06e-05 | 126 |
| GO:00343411 | Liver | HCC | response to interferon-gamma | 82/7958 | 141/18723 | 1.25e-04 | 1.03e-03 | 82 |
| GO:00713461 | Liver | HCC | cellular response to interferon-gamma | 70/7958 | 118/18723 | 1.66e-04 | 1.32e-03 | 70 |
| GO:005159121 | Liver | HCC | response to cAMP | 57/7958 | 93/18723 | 1.96e-04 | 1.52e-03 | 57 |
| GO:001407421 | Liver | HCC | response to purine-containing compound | 84/7958 | 148/18723 | 3.19e-04 | 2.26e-03 | 84 |
| GO:007133112 | Liver | HCC | cellular response to hexose stimulus | 85/7958 | 153/18723 | 7.47e-04 | 4.52e-03 | 85 |
| GO:007132612 | Liver | HCC | cellular response to monosaccharide stimulus | 85/7958 | 154/18723 | 9.78e-04 | 5.68e-03 | 85 |
| GO:007132212 | Liver | HCC | cellular response to carbohydrate stimulus | 89/7958 | 163/18723 | 1.19e-03 | 6.62e-03 | 89 |
| GO:004668321 | Liver | HCC | response to organophosphorus | 73/7958 | 131/18723 | 1.52e-03 | 8.05e-03 | 73 |
| GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
| GO:00508926 | Liver | HCC | intestinal absorption | 25/7958 | 41/18723 | 1.31e-02 | 4.69e-02 | 25 |
| GO:00713205 | Liver | HCC | cellular response to cAMP | 31/7958 | 53/18723 | 1.37e-02 | 4.87e-02 | 31 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0520842 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
| hsa0520852 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC26A6 | SNV | Missense_Mutation | c.1901N>C | p.Ser634Thr | p.S634T | Q9BXS9 | protein_coding | tolerated(0.36) | benign(0.012) | TCGA-A8-A07F-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| SLC26A6 | SNV | Missense_Mutation | c.1873G>A | p.Val625Ile | p.V625I | Q9BXS9 | protein_coding | tolerated(0.28) | benign(0.021) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SLC26A6 | SNV | Missense_Mutation | rs374322645 | c.2264C>T | p.Ser755Leu | p.S755L | Q9BXS9 | protein_coding | tolerated(1) | benign(0) | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC26A6 | SNV | Missense_Mutation | rs551934028 | c.1939N>G | p.Gln647Glu | p.Q647E | Q9BXS9 | protein_coding | tolerated(0.52) | benign(0.02) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC26A6 | SNV | Missense_Mutation | rs765049864 | c.430G>A | p.Val144Met | p.V144M | Q9BXS9 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| SLC26A6 | SNV | Missense_Mutation | novel | c.1592N>G | p.Tyr531Cys | p.Y531C | Q9BXS9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SLC26A6 | SNV | Missense_Mutation | c.1011N>A | p.Asn337Lys | p.N337K | Q9BXS9 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-DM-A28F-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| SLC26A6 | deletion | Frame_Shift_Del | c.1618delG | p.Val540Ter | p.V540* | Q9BXS9 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |||
| SLC26A6 | deletion | Frame_Shift_Del | c.1618delN | p.Val540Ter | p.V540* | Q9BXS9 | protein_coding | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |||
| SLC26A6 | deletion | Frame_Shift_Del | c.913delN | p.Ala305ProfsTer10 | p.A305Pfs*10 | Q9BXS9 | protein_coding | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |